Equities

Senti Biosciences Inc

SNTI:NAQ

Senti Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.17
  • Today's Change0.051 / 2.39%
  • Shares traded7.08k
  • 1 Year change-37.93%
  • Beta2.7212
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments369956
Total Receivables, Net180.630.48
Total Inventory------
Prepaid expenses171.87--
Other current assets, total0.241.523.68
Total current assets7110360
Property, plant & equipment, net427533
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term1.12----
Other long term assets2.030.290.18
Total assets11918197
LIABILITIES
Accounts payable1.252.275.19
Accrued expenses9.96157.07
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.10----
Other current liabilities, total1.370.932.28
Total current liabilities131815
Total long term debt000
Total debt0.1000
Deferred income tax------
Minority interest------
Other liabilities, total403522
Total liabilities535436
SHAREHOLDERS EQUITY
Common stock0.010.000.00
Additional paid-in capital3113013.62
Retained earnings (accumulated deficit)(244)(173)(115)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total00.00--
Total equity6712760
Total liabilities & shareholders' equity11918197
Total common shares outstanding4.574.414.37
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.